Is Fatty Liver Disease Common in Older Adults?

Fatty liver disease is remarkably common in older adults, affecting roughly two in five people over age 60 in the United States. That figure makes it one of the most prevalent chronic liver conditions in the aging population, yet it remains widely underdiagnosed because it rarely causes symptoms in its early stages. What makes fatty liver disease in older adults particularly worth understanding is not just how common it is, but how differently it behaves compared to the same condition in younger people.

How Common It Actually Is

Studies using nationally representative U.S. data place the prevalence of nonalcoholic fatty liver disease (NAFLD) at about 40% among adults aged 60 to 74, with a nearly identical rate of around 39% in those over 74.¹ A separate analysis of U.S. adults 65 and older, using the newer “MASLD” classification (more on that name change below), found a comparable rate of about 40%.² These numbers are not a quirk of one dataset. A global burden-of-disease analysis estimated roughly 228 million cases of fatty liver disease in elderly populations worldwide, contributing to about 87,000 deaths annually.³

What often surprises people is that the prevalence does not drop off dramatically in the oldest age groups. You might expect an 80-year-old to be less likely to have fatty liver than a 65-year-old, but the data suggest the rates hold fairly steady into advanced age. This partly reflects a survivorship effect, but it also reflects how persistently metabolic factors like insulin resistance, obesity, and sedentary habits accumulate over decades.

Why the Aging Liver Accumulates Fat

The liver changes in meaningful ways as you age. At a cellular level, mitochondria, the energy-producing structures inside liver cells, become less efficient. Their ability to burn fat through a process called beta-oxidation declines, while their production of damaging molecules called reactive oxygen species increases.⁴ This creates a one-two punch: less fat gets burned, and what remains inflicts more damage on liver tissue. Animal research has confirmed that aging is associated with declines in key proteins that keep mitochondria functioning and renewing themselves, which correlates with increased fat deposits in the liver.⁵

On top of these mitochondrial changes, the aging liver undergoes broader shifts. Genetic and epigenetic alterations accumulate, cells become senescent (meaning they stop dividing but stay metabolically active and inflamed), and the liver’s ability to sense and respond to nutrients deteriorates.⁶ The gut may also play a role: age-related changes in gut bacteria can increase intestinal permeability, drive systemic inflammation, and alter the metabolism of bile acids and other compounds that the liver has to process.⁷ None of these changes guarantee fatty liver, but they create a biological environment that makes fat accumulation in the liver much easier.

Why Women Catch Up After Menopause

Before menopause, women tend to have lower rates of fatty liver disease than men. After menopause, that gap narrows and in some studies reverses entirely. The key factor is estrogen. Estrogen appears to protect the liver by reducing inflammation, improving insulin sensitivity, supporting mitochondrial function, and slowing fibrosis.⁸ When estrogen levels drop, the postmenopausal metabolic shift promotes dyslipidemia and insulin resistance, driving more free fatty acids into the liver.

The prevalence of fatty liver disease increases not only in women who go through natural menopause but also in those with premature ovarian insufficiency or surgical menopause.⁸ Among older adults with fatty liver disease, women with established conditions like polycystic ovary syndrome or estrogen deficiency carry increased risk, and mortality rates in older women with this condition can exceed those in men of the same age.⁹ This is an area where sex-specific awareness matters, because women and their doctors may not associate fatty liver with postmenopausal health.

Muscle Loss and Fatty Liver Feed Each Other

One of the most consequential and underappreciated connections in older adults is the link between muscle loss (sarcopenia) and fatty liver disease. These two conditions tend to travel together and actively worsen each other. A ten-year retrospective study found that both increased fat mass and decreased skeletal muscle mass with aging were independently associated with developing new fatty liver disease, in both men and women.¹⁰

The relationship goes both ways. People who lost muscle mass over a six-year period showed worsening liver fat, while those who already had sarcopenia at the start saw greater increases in liver fibrosis scores.¹¹ The mechanisms driving this two-way relationship include insulin resistance, chronic low-grade inflammation, oxidative stress, and signaling molecules exchanged between liver, fat, and muscle tissue.¹²

When the two conditions coexist, the health consequences escalate sharply. In a study of older Americans followed for a median of nearly 17 years, people who had both fatty liver disease and sarcopenia faced about 1.7 times the risk of dying from any cause and about 2.2 times the risk of dying from cardiovascular disease, compared to those with neither condition.¹³ This overlap is one reason clinicians are increasingly concerned about fatty liver disease in geriatric patients: it is not just a liver problem.

You Can Be Thin and Still Have It

A persistent misconception is that fatty liver disease only affects people who are overweight. A meaningful subset of cases occurs in people with a normal body mass index, a pattern sometimes called “lean NAFLD.” Among lean patients with fatty liver disease, those aged 60 and older showed higher rates of hypertension, diabetes, and abnormal cholesterol, as well as more advanced liver inflammation and fibrosis, compared to younger lean patients with the same diagnosis. Older lean patients also tended to have lower muscle mass and weaker grip strength.¹⁴ The takeaway is that being at a healthy weight does not protect an older adult from fatty liver, and the condition should not be dismissed on the basis of body size alone.

How Progression Differs With Age

One of the more nuanced findings in the research is that the rate at which fatty liver advances to cirrhosis does not appear to differ much by age. A large study found that the ten-year risk of developing cirrhosis was around 3 to 5 percent regardless of whether someone was in their 30s, 50s, or over 60.¹⁵ What does increase with age, though, is the likelihood of liver-related events once you have the condition. In other words, the road to serious liver damage is about the same length at any age, but older adults are more vulnerable to complications along the way.

When fatty liver disease does progress to cirrhosis in older adults, the consequences are harder to manage. A study of older Americans with cirrhosis found significantly worse self-reported health, more hospitalizations, greater disability in daily activities, and more than double the informal caregiving hours per week compared to age-matched peers without the condition.¹⁶ Frailty compounds the problem: it has been identified in nearly half of patients with cirrhosis, creating a cycle of declining function that is difficult to reverse.

Why Standard Screening Tests Can Mislead in Older Adults

A practical challenge clinicians face is that the most widely used screening tool for liver fibrosis, called the FIB-4 index, factors in the patient’s age. That makes it unreliable for older adults if standard cutoff values are applied. The standard low cutoff for ruling out advanced fibrosis is 1.3, and the high cutoff for ruling it in is 2.67. In older adults, these thresholds produce too many false positives because age alone pushes the score up. Research on age-specific cutoffs has proposed adjusted values: for people in their 60s, the low cutoff should be closer to 1.88, and for those 70 and older, around 1.95.¹⁷

Even with adjusted cutoffs, the test performs differently depending on the threshold used. In adults 65 and older, using a FIB-4 below 1.3 had a perfect negative predictive value for ruling out significant fibrosis, meaning everyone below that cutoff truly did not have advanced scarring. But higher thresholds were less reliable and were significantly affected by the patient’s age.¹⁸ If your doctor orders a FIB-4 test and you are over 65, the result needs to be interpreted through an age-aware lens. A score that looks alarming in a 40-year-old might be perfectly normal for a 75-year-old.

Despite the high prevalence and the diagnostic pitfalls, there are still no widely adopted global screening guidelines for fatty liver disease in high-risk older adults.¹⁹ That means many older people walk around with undiagnosed fatty liver disease, sometimes for years, until another health event prompts a closer look at the liver.

Damage Beyond the Liver

Fatty liver disease in older adults is not just a liver story. It is increasingly recognized as a systemic condition that raises risks across multiple organ systems.

Heart disease is the leading cause of death in people with fatty liver disease, not liver failure. Among elderly patients who had a heart attack, those with concurrent fatty liver disease experienced significantly more cardiovascular complications, including heart rhythm instability and hemodynamic collapse, than those without it.¹⁶ In older adults who already had atrial fibrillation, the presence of fatty liver disease was independently associated with roughly a 22% higher risk of developing heart failure.²

The kidneys also take a hit. In middle-aged and older adults, fatty liver disease has been linked to chronic kidney disease even after accounting for the usual suspects like diabetes and high blood pressure. In one study of adults 50 and older, NAFLD was associated with about 68% higher odds of chronic kidney disease.²⁰ In older adults with type 2 diabetes and fatty liver, more advanced liver fibrosis predicted faster kidney decline in a graded fashion: the higher the fibrosis score, the more likely the kidneys deteriorated over five years.²¹

Perhaps the most unsettling link is with dementia. A population-based cohort study following patients for a median of more than five years found that people with fatty liver disease had roughly 38% higher rates of developing dementia. The risk was especially pronounced when fatty liver coexisted with heart disease or stroke: in people who had both fatty liver and a history of stroke, the dementia risk more than doubled.²²

Racial and Ethnic Differences in Risk

Fatty liver disease does not affect all demographic groups equally. Using the updated diagnostic criteria, Hispanic Americans consistently show the highest prevalence of steatotic liver disease in the U.S., while Black Americans tend to have the lowest rates, despite often carrying heavier burdens of metabolic syndrome components like diabetes and hypertension. Interestingly, once the disease is present, the risk of advanced fibrosis does not differ significantly by race or ethnicity.²³

The pattern becomes more complex when sex is factored in. Mexican-American and Black women with fatty liver disease have been found to carry a more severe metabolic burden than white women with the same diagnosis. Among men, the picture is different: Black men tend to have lower metabolic syndrome severity scores than white men.²⁴ These disparities underscore that one-size-fits-all screening and management strategies are likely to miss high-risk individuals in certain populations.

The Name Change and What It Means

If you have been reading about this topic and noticed the condition being called different things, you are not confused. In 2023, international hepatology societies officially renamed “nonalcoholic fatty liver disease” (NAFLD) to “metabolic dysfunction-associated steatotic liver disease” (MASLD). The change reflected a scientific consensus that the condition is fundamentally driven by metabolic factors and that the old name, defined by what the disease was not (“nonalcoholic”), was both stigmatizing and imprecise.

The new classification also introduced a category called MetALD, which applies to people who have fatty liver with metabolic risk factors and also drink moderate amounts of alcohol. For women, that means roughly 20 to 50 grams per day; for men, 30 to 60 grams.²⁵ This matters for older adults in particular because moderate alcohol use is relatively common in that age group and was previously a diagnostic gray area. A study of older adults with atrial fibrillation found that those with MetALD had a 36% higher risk of developing heart failure compared to those without any liver disease, a risk slightly above that seen with MASLD alone.² If you drink even moderately and have metabolic risk factors, the MetALD label acknowledges that both contributors may be worsening your liver health.

Polypharmacy and the Medication Pile-Up

Older adults with fatty liver disease tend to take a lot of medications, and the problem compounds with age. Among U.S. adults 75 and older with MASLD, about 60% met the threshold for polypharmacy, defined as regularly taking five or more prescription drugs. That rate was significantly higher than both younger adults with the same liver condition and same-age peers without it. Compared to 65-to-69-year-olds with MASLD, those 75 and older had more than three times the odds of polypharmacy.²⁶

This is not just a bookkeeping issue. Many of the conditions that travel with fatty liver disease, including diabetes, high blood pressure, high cholesterol, and kidney disease, each come with their own medications. The liver processes most drugs, and a liver that is inflamed or scarred may handle them differently. Drug interactions become harder to predict, side effects become harder to attribute, and adherence becomes harder to maintain. Clinicians managing fatty liver disease in older patients often find themselves navigating a web of medications where removing one drug may be as important as adding another.

The Gut Connection

The composition of bacteria in the gut changes with age, and emerging research ties those changes to liver health. As people get older, they tend to lose diversity in their gut microbiome, which can increase intestinal permeability. When the gut barrier becomes leaky, bacterial products and inflammatory signals reach the liver more easily, potentially fueling fat accumulation and inflammation. Age-related gut dysbiosis also alters the production of short-chain fatty acids and bile acids, both of which play important roles in liver metabolism.⁷ This is still an active area of research rather than settled science, but it points to the gut as another reason the aging body is primed to develop fatty liver disease. Whether interventions targeting the gut microbiome can slow or prevent the condition in older adults remains to be seen.

1
PubMed Central. Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States
2
PubMed. Coexistence of atrial fibrillation and metabolic dysfunction-associated steatotic liver disease as a high-risk overlap for incident heart failure in older adults
3
PubMed. The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis
4
PubMed Central. Research progress on the mitochondrial mechanism of age-related non-alcoholic fatty liver
5
PubMed. Evidence for association of mitochondrial metabolism alteration with lipid accumulation in aging rats
6
Computational and Structural Biotechnology Journal. Hallmarks of Aging in the Liver
7
PubMed. Impacts of gut microbiota alteration on age-related chronic liver diseases
8
PubMed. The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause
9
JHEP Reports. Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts
10
PubMed Central. Age-Related Decrease in Skeletal Muscle Mass Is an Independent Risk Factor for Incident Nonalcoholic Fatty Liver Disease: A 10-Year Retrospective Cohort Study
11
Scientific Reports. Change in skeletal muscle mass is associated with hepatic steatosis in nonalcoholic fatty liver disease
12
PubMed Central. Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?
13
Scientific Reports. Sarcopenia modifies the associations of nonalcoholic fatty liver disease with all-cause and cardiovascular mortality among older adults
14
PubMed. Lean nonalcoholic fatty liver disease: Age-dependent differences in pathology, prognosis, and liver-related events
15
PubMed Central. Progression to cirrhosis is similar among all ages in nonalcoholic fatty liver disease, but liver-related events increase with age
16
PubMed Central. Analysis of Risk Factors for Adverse Cardiovascular Events in Elderly Patients with Acute Myocardial Infarction and Non-Alcoholic Fatty Liver Disease
17
PubMed. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study
18
PubMed Central. Age-dependent differences in FIB-4 predictions of fibrosis in patients with MASLD referred from primary care
19
PubMed Central. Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic
20
PubMed Central. Non-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Koreans Aged 50 Years or Older
21
The Journal of Clinical Endocrinology & Metabolism. Fibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients
22
Neurology. Nonalcoholic Fatty Liver Disease and Risk of Dementia: A Population-Based Cohort Study
23
Communications Medicine. Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria
24
PLOS ONE. The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease
25
International Journal of Obesity. Weight loss and alcohol reduction synergize for hepatic steatosis remission in elderly patients with metabolic alcohol-associated liver disease (MetALD): a retrospective cohort study
26
International Journal of Obesity. Polypharmacy Among Older Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease